S272: SAFETY AND PRELIMINARY PHARMACODYNAMIC EFFECTS OF THE FERROPORTIN INHIBITOR VAMIFEPORT (VIT-2763) IN PATIENTS WITH NON-TRANSFUSION-DEPENDENT BETA THALASSEMIA (NTDT): RESULTS FROM A PHASE 2A STUDY

S272: SAFETY AND PRELIMINARY PHARMACODYNAMIC EFFECTS OF THE FERROPORTIN INHIBITOR VAMIFEPORT (VIT-2763) IN PATIENTS WITH NON-TRANSFUSION-DEPENDENT BETA THALASSEMIA (NTDT): RESULTS FROM A PHASE 2A STUDY

Bibliographic Details
Main Authors:	A. Taher, A. Kourakli-Symeonidis, A. Tantiworawit, P. Wong, P. Szecsödy
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000843980.18213.bf

Similar Items

The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia
by: Naja Nyffenegger, et al.
Published: (2021-01-01)

Structures of ferroportin in complex with its specific inhibitor vamifeport
by: Elena Farah Lehmann, et al.
Published: (2023-03-01)

Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy
by: Musallam KM, et al.
Published: (2023-05-01)

P1510: VAMIFEPORT PREVENTED THE FORMATION OF NON-TRANSFERRIN-BOUND IRON IN A MOUSE MODEL OF ΒETA-THALASSEMIA WITH BLOOD TRANSFUSIONS
by: N. Kalleda, et al.
Published: (2022-06-01)

S273: LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL
by: Ali T. Taher, et al.
Published: (2023-08-01)

Effects of transfusion and splenectomy on globin chain expression in NTDT HbE/β-thalassaemia
by: Lim, Wai Feng, et al.
Published: (2021)

Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia
by: Ali T Taher, et al.
Published: (2023-03-01)

Recent advances in molecular understanding of NTDT: 2012
by: Vip Viprakasit
Published: (2013-03-01)

Leukocyte telomere length in patients with transfusion-dependent thalassemia
by: Nithita Nanthatanti, et al.
Published: (2020-06-01)

Heart Rate Variability for Early Detection of Cardiac Iron Deposition in Patients with Transfusion-Dependent Thalassemia.
by: Suchaya Silvilairat, et al.
Published: (2016-01-01)

Ferroportin: lack of evidence for multimers.
by: Schimanski, L, et al.
Published: (2008)

Non-transfusion dependent thalassemia: translating evidence to guidelines
by: Afif R. Harb, et al.
Published: (2014-12-01)

Quality of life: Transfusion dependent thalassemia vs non-transfusion dependent thalassemia
by: Mehran Karimi, et al.
Published: (2018-04-01)

Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management
by: Joseph Sleiman, et al.
Published: (2018-01-01)

Transfusion regimens in thalassemia intermedia
by: Z. Karakas
Published: (2011-12-01)

Osteoporosis in Transfusion Dependent Thalassemia
by: Mozhgan Hashemieh
Published: (2019-11-01)

P1506: REAL-WORLD DATA ON THE USE OF LUSPATERCEPT IN GREEK PATIENTS WITH TRANSFUSION DEPENDENT THALASSEMIA
by: P. Delaporta, et al.
Published: (2022-06-01)

The role of red cell distribution width in the differential diagnosis of iron deficiency anemia and non-transfusion dependent thalassemia patients
by: Pokpong Piriyakhuntorn, et al.
Published: (2018-09-01)

THE ROLES OF HEPCIDIN AND FERROPORTIN IN AUTOCRINE REGULATION OF IRON LEVELS
by: Lakhal-Littleton, S, et al.
Published: (2013)

Luspatercept for transfusion-dependent β-thalassemia: time to get real
by: Khaled M. Musallam, et al.
Published: (2023-08-01)

Primary Lamellar Macular Holes: To Vit or Not to Vit
by: Lihteh Wu, et al.
Published: (2022-08-01)

Mechanism of Ca2+ transport by ferroportin
by: Jiemin Shen, et al.
Published: (2023-01-01)

Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions
by: Saliba AN, et al.
Published: (2015-06-01)

A Cross-Sectional, Multicentric, Disease-Specific, Health-Related Quality of Life Study in Greek Transfusion Dependent Thalassemia Patients
by: Klonizakis, P, et al.
Published: (2024)

Multiresidue Pesticide Analysis in Tea Using GC–MS/MS to Determine 12 Pesticide Residues (GB 2763-2021)
by: Kunming Zheng, et al.
Published: (2022-12-01)

5588005 IMPACT OF COVID-19 PANDEMIC TO PRE-TRANSFUSION HEMOGLOBIN LEVEL AND FREQUENCY OF TRANSFUSION IN TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS IN INDONESIA
by: M.K.D. Dewi, et al.
Published: (2023-04-01)

Transfusion-induced hemoglobinopathy in patients of beta-thalassemia major
by: Sanjeev K Gupta, et al.
Published: (2011-01-01)

Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin.
by: Drakesmith, H, et al.
Published: (2005)

A randomized placebo−controlled clinical trial of oral green tea epigallocatechin 3−gallate on erythropoiesis and oxidative stress in transfusion−dependent β−thalassemia patients
by: Kornvipa Settakorn, et al.
Published: (2024-01-01)

The Role of Copper in the Regulation of Ferroportin Expression in Macrophages
by: Aneta Jończy, et al.
Published: (2021-08-01)

Structural basis of ion transport and inhibition in ferroportin
by: Yaping Pan, et al.
Published: (2020-11-01)

Use of Deferasirox Film-Coated Tablets in Pediatric Patients with Transfusion Dependent Thalassemia: A Single Center Experience
by: Alkistis Adramerina, et al.
Published: (2022-02-01)

Glomerular and Tubular Functions in Transfusion-Dependent Thalassemia
by: Pathum Sookaromdee, et al.
Published: (2018-05-01)

Iron overload in non-transfusion-dependent thalassemia
by: Khaled M. Musallam
Published: (2013-03-01)

Alloimmunization among transfusion-dependent thalassemia patients
by: Sadeghian Mohammad, et al.
Published: (2009-01-01)

Physical growth in children with transfusion-dependent thalassemia
by: Harish K Pemde, et al.
Published: (2011-02-01)

Heart Rate Variability as an Alternative Indicator for Identifying Cardiac Iron Status in Non-Transfusion Dependent Thalassemia Patients.
by: Karn Wijarnpreecha, et al.
Published: (2015-01-01)

Transfusion Transmitted Infections in Multiple Transfused Thalassemia Patients in Rahim Yar Khan
by: Muhammad Bilal Ghafoor, et al.
Published: (2021-03-01)

Effects of Vitamin E on Transfusion Requirements in TransfusionDependent Beta-Thalassemia Patients
by: Duangdee Trangsuwan, et al.
Published: (2018-08-01)

Occult Kidney Dysfunction in Children With Transfusion-Dependent Thalassemia
by: Nurwahida Mohd Zikre, et al.
Published: (2021-11-01)